Pharmaceutical supply chains are complex and global, spanning APIs, CROs/CDMOs, packaging partners, IT vendors, and more. These relationships are essential to compliance and business continuity, but weak contract execution often leads to missed obligations, rising costs, and hidden risks.
Research shows that companies lose nearly 9% of contract value after contracts are signed—but with stronger oversight, clearer enforcement, and better control over pricing, that value doesn’t have to stay lost.
This guide offers practical strategies to close those gaps. By embedding accountability, tracking performance, and strengthening oversight, pharmaceutical companies can protect compliance and recover value that should stay in the business.
In this guide, you’ll learn:
- Why post-signature oversight is the most common point of value leakage
- How to prevent risks like price creep and missed deliverables
- Which supplier categories carry the greatest compliance and financial risks
- Steps to build stronger governance that safeguards margins and compliance